Browsing Tag
NASDAQ
807 posts
Range Capital Acquisition Corp. II prices $200m IPO — What it means for SPAC investors and Nasdaq sentiment
Range Capital Acquisition Corp. II prices $200M IPO on Nasdaq — see how this SPAC plans to hunt deals and why investors are watching its next move.
Nanyang Biologics to list via $1.5bn SPAC — What it means for The9 investors and biotech markets
The9-backed Nanyang Biologics plans a $1.5B SPAC listing on Nasdaq. Find out what this means for AI drug discovery, The9’s stock, and investors.
Why Viomi Technology’s Nasdaq compliance matters more than just avoiding delisting
Viomi Technology (NASDAQ: VIOT) regains Nasdaq compliance. See why it matters for investors, stock sentiment, governance, and the water purification industry.
Germany’s DeepL eyes $5bn U.S. IPO — Can it really rival Google and Microsoft in AI translation?
DeepL is considering a $5B U.S. IPO to expand its AI translation and agent business—find out how this move could reshape the language tech industry.
From zero revenue to $13bn valuation: What Fermi’s blockbuster debut tells investors about AI data centers
Fermi’s IPO soared 19% above its issue price, spotlighting investor appetite for AI-driven infrastructure. Find out what this REIT debut means for markets today.
Alphabet’s cloud layoffs explained: How Wall Street is reading GOOGL’s efficiency push
Alphabet (NASDAQ: GOOGL) trims jobs in Google Cloud amid efficiency push. Explore what it means for investors, enterprise clients, and AI competition.
Fermi America prices IPO at $21 per share ahead of Nasdaq and London listings
Fermi America prices IPO at $21, dual-listing on Nasdaq and London. Find out why investors see FRMI as a bold bet on AI-driven energy grids.
Texas Stock Exchange gains SEC approval, opening a new era of competition in U.S. capital markets
The SEC has approved TXSE Group’s Texas Stock Exchange, creating new competition for NYSE and Nasdaq. Find out how TXSE could reshape U.S. markets.
Klotho Neurosciences expands beyond the anti-aging gene with Turn Biotechnologies acquisition plan
Klotho Neurosciences moves to buy Turn Bio’s ERA and eTurna assets plus a $300M Korea pharma deal. Explore how this could reshape its longevity pipeline.
How Nuvini’s acquisition of MK Solutions could change Brazil’s ERP market forever
Nuvini Group’s acquisition of MK Solutions adds R$40M revenue and R$20M EBITDA. Find out what this means for SaaS growth and investor sentiment.